4/14/2022 8:34:26 AM
PTC Updates On EMA Regulatory Review Timeline For AADC Deficiency Gene Therapy Program; CHMP Opinion Expected May 2022
1/10/2022 7:14:44 AM
PTC Therapeutics Reports $536 Mln 2021 Total Revenue Represents 41% Year-over-year Growth
1/4/2022 8:07:44 AM
Waylivra Gets Innovative Drug Category Pricing To Treat Familial Chylomicronemia Syndrome In Brazil
10/14/2021 8:32:46 AM
PTC Therapeutics Reports Opening Of Gene Therapy Manufacturing Facility In Hopewell, N.J.
10/11/2021 8:18:29 AM
PTC Therapeutics: Tegsedi Gets Category 1 Classification From CMED In Brazil
9/29/2021 8:06:39 AM
PTC Therapeutics: Results Show Improvements In Children With AADC Deficiency Treated With PTC-AADC Gene Therapy
9/20/2021 8:38:25 AM
PTC Therapeutics : Data Show Translarna Delays Loss Of Ambulation By Over 5yrs In Boys With NmDMD
6/9/2021 8:13:50 AM
PTC Therapeutics Elects Mary Smith To Board
5/26/2021 8:11:13 AM
PTC Therapeutics: FDA And EC Grant Orphan Drug Designation For PTC923 For Patients With Hyperphenylalaninemia